Design Therapeutics Directors Bulk 30‑K Zero‑Cost Options: A Coordinated Bet on a Breakthrough Amid 52‑Week Low Price <|end|>
Insider momentum at Design Therapeutics signals confidence in a breakthrough despite low shares—watch options, clinical milestones and potential upside.
2 minutes to read
